Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors.

Donna L JohnstonSusan ZupanecDarcy NicksyDaniel A MorgensternAru NarendranRebecca J DeyellYvan SamsonBing WuSylvain Baruchel

Published in: Pediatric blood & cancer (2019)

Melatonin is well tolerated at a dose of 0.3 mg/kg (maximum 20 mg), in the pediatric population. This study provides the background for further study of high-dose melatonin in pediatric oncology patients.

Keyphrases

high dose
palliative care
end stage renal disease
chronic kidney disease
low dose
acute myeloid leukemia
diffuse large b cell lymphoma
young adults
prognostic factors
peritoneal dialysis
patient reported outcomes